Ruth Gimeno: useful biomarkers need outcome studies
LinkedIn caption
Ruth Gimeno in conversation at ARDD 2026. 🔬 On the conference’s diseases-and-longevity panel, she highlighted a practical challenge: having many candidate biomarkers is only a starting point. The field still needs to validate which measurements are useful, and outcome studies remain essential.
She also distinguished diseases with specific, targetable risk factors from systemic conditions that share features with aging. That perspective connects her work in diabetes, obesity and cardiometabolic research at Eli Lilly with the wider challenge of developing longevity therapeutics.
A community moment alongside those scientific discussions. 🤝
Photo credit: Donis Perkins and Alex Zhavoronkov.
#ARDD2026 #Biomarkers
X caption
Ruth Gimeno at #ARDD2026. 🔬 Her panel remarks emphasized validating useful biomarkers and conducting outcome studies, alongside disease-based routes to longevity therapeutics.
Photo: Donis Perkins and Alex Zhavoronkov.
Photo: Donis Perkins and Alex Zhavoronkov
Copy and paste the caption manually, then attach the downloaded photo. Nothing is published automatically.
